Next Article in Journal
Transcriptome Sequencing Analyses between the Cytoplasmic Male Sterile Line and Its Maintainer Line in Welsh Onion (Allium fistulosum L.)
Next Article in Special Issue
Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer
Previous Article in Journal
Effects and Mechanisms of Low-Intensity Pulsed Ultrasound for Chronic Prostatitis and Chronic Pelvic Pain Syndrome
Previous Article in Special Issue
The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2016, 17(7), 1056;

Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma

Center for Integrated Oncology (CIO), Medizinische Klinik und Poliklinik III, University of Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
Hochschule Bonn-Rhein-Sieg, 53359 Rheinbach, Germany
Author to whom correspondence should be addressed.
Academic Editor: M. Rita I. Young
Received: 3 May 2016 / Revised: 21 June 2016 / Accepted: 24 June 2016 / Published: 1 July 2016
Full-Text   |   PDF [849 KB, uploaded 1 July 2016]   |  


Brentuximab vedotin (SGN-35) is an antibody–drug conjugate with a high selectivity against CD30+ cell lines and more than 300-fold less activity against antigen-negative cells. In the last years, the results of many in vitro and in vivo studies have led to the fast approval of this drug to treat lymphoma patients. Another innovative method to treat tumor cells including lymphoma cells is the use cytokine-induced killer (CIK) cells, which have also been approved and proven to be a safe treatment with only minor adverse events. In this study, a possible additive effect when combining SGN-35 with CIK cells was investigated. The combinational treatment showed that it reduces the viability of CD30+ cell lines significantly in vitro. Additionally, the amount of lymphoma cells was significantly reduced when exposed to CIK cells as well as when exposed to SGN-35. A significant negative effect of SGN-35 on the function of CIK cells could be excluded. These results lead to the assumption that SGN-35 and CIK cells in combination might achieve better results in an in vitro setting compared to the single use of SGN-35 and CIK cells. Further investigations in in vivo models must be conducted to obtain a better understanding of the exact mechanisms of both treatments when applied in combination. View Full-Text
Keywords: lymphoma; cytokine-induced killer (CIK) cells; antibody–drug conjugate; SGN-35; CD30+ cells lymphoma; cytokine-induced killer (CIK) cells; antibody–drug conjugate; SGN-35; CD30+ cells

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Esser, L.; Weiher, H.; Schmidt-Wolf, I. Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma. Int. J. Mol. Sci. 2016, 17, 1056.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top